Cargando…

Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway

The tumor microenvironment has been recently recognized as a critical contributor to cancer progression and anticancer therapy-resistance. Cyclophosphamide (CTX) is a cytotoxic agent commonly used in clinics for the treatment of cancer. Previous reports demonstrated that CTX given at low continuous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Hui, Lai, Yifan, Zhang, Rui, Daoud, Abdelkader, Feng, Qingyuan, Zhou, Jia, Shang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038197/ https://www.ncbi.nlm.nih.gov/pubmed/32023984 http://dx.doi.org/10.3390/ijms21030957

Ejemplares similares

A Small β-Carboline Derivative “B-9-3” Modulates TGF-β Signaling Pathway Causing Tumor Regression in Vivo
por: Zhong, Hui, et al.
Publicado: (2018)

Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
por: Chen, Xin, et al.
Publicado: (2014)

Integrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment
por: Brown, Nicholas F., et al.
Publicado: (2019)

Low-dose cyclophosphamide-induced acute hepatotoxicity
por: Subramaniam, S. Ravih, et al.
Publicado: (2013)

Low-Dose Cyclophosphamide Associated With Hyponatremia and Hepatotoxicity
por: DeChiara, James R, et al.
Publicado: (2023)

TGFβ Signaling in the Pancreatic Tumor Microenvironment
por: Principe, Daniel R., et al.
Publicado: (2021)

TGFβ and the Tumor Microenvironment in Colorectal Cancer
por: Waldner, Maximilian J., et al.
Publicado: (2023)

Water Intoxication Following Low-Dose Intravenous Cyclophosphamide
por: Koo, Tai Yeon, et al.
Publicado: (2007)

Organ microenvironment affects growth and metastasis of hepatocellular carcinoma via the TGF-β/Smad pathway in mice
por: LI, GUOCAI, et al.
Publicado: (2013)

Fibulin-3 is a Novel TGF-β pathway Inhibitor in the Breast Cancer Microenvironment
por: Tian, Hongyu, et al.
Publicado: (2015)

Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis
por: Huang, Xiao-Ming, et al.
Publicado: (2019)

Effective Chemoimmunotherapy with Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer
por: Chen, Xin, et al.
Publicado: (2014)

TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer
por: Caja, Laia, et al.
Publicado: (2018)

The role of TGF-β in the tumor microenvironment of pancreatic cancer
por: Luo, Qiang, et al.
Publicado: (2022)

The Smad Dependent TGF-β and BMP Signaling Pathway in Bone Remodeling and Therapies
por: Zou, Ming-Li, et al.
Publicado: (2021)

TGFβ1 microenvironment determines dendritic cell development
por: Seré, Kristin, et al.
Publicado: (2013)

MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer
por: Guo, Lingling, et al.
Publicado: (2015)

TGF-β Signaling: From Tissue Fibrosis to Tumor Microenvironment
por: Chung, Jeff Yat-Fai, et al.
Publicado: (2021)

TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
por: Shi, Xueke, et al.
Publicado: (2022)

The Great Capacity on Promoting Melanogenesis of Three Compatible Components in Vernonia anthelmintica (L.) Willd.
por: Lai, Yifan, et al.
Publicado: (2021)

Low-Dose Cyclophosphamide Induces Nerve Injury and Functional Overactivity in the Urinary Bladder of Rats
por: Wang, Rui, et al.
Publicado: (2021)

Stromal Modulators of TGF-β in Cancer
por: Costanza, Brunella, et al.
Publicado: (2017)

Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review)
por: PAPAGEORGIS, PANAGIOTIS, et al.
Publicado: (2015)

TGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment
por: Angioni, Roberta, et al.
Publicado: (2021)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
por: Veltman, Joris D., et al.
Publicado: (2010)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

Peyronie's Disease Treated with Oral Weekly Dexamethasone and Continuous Low-dose Cyclophosphamide
por: Gupta, Ramji, et al.
Publicado: (2014)

Effects of imipenem combined with low-dose cyclophosphamide on the intestinal barrier in septic rats
por: Guo, Peng, et al.
Publicado: (2018)

Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma
por: Machado, Marília Carneiro, et al.
Publicado: (2022)

CCN5 Reduces Ligamentum Flavum Hypertrophy by Modulating the TGF‐β Pathway
por: Ye, Sunghyeok, et al.
Publicado: (2019)

Modulation of the TGF-β signaling pathway by long noncoding RNA in hepatocellular carcinoma
por: Han, Mengzhen, et al.
Publicado: (2020)

Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study
por: Lan, Yingxia, et al.
Publicado: (2023)

Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases
por: He, Kewen, et al.
Publicado: (2021)

CHPF Regulates the Aggressive Phenotypes of Hepatocellular Carcinoma Cells via the Modulation of the Decorin and TGF-β Pathways
por: Liu, Chiung-Hui, et al.
Publicado: (2021)

Extracellular HMGB1 Contributes to the Chronic Cardiac Allograft Vasculopathy/Fibrosis by Modulating TGF-β1 Signaling
por: Zou, Huijuan, et al.
Publicado: (2021)

A risk score model based on TGF-β pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma
por: Liao, Jingsheng, et al.
Publicado: (2022)

An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment
por: DePeaux, Kristin, et al.
Publicado: (2023)

miR-211 alleviates ischaemia/reperfusion-induced kidney injury by targeting TGFβR2/TGF-β/SMAD3 pathway
por: Shang, Jinchun, et al.
Publicado: (2020)

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
por: Patten, Steven G, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2d8vc632u8mgr1uc1ah147ufgc